Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma.

Autor:	Pandith AA; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Qasim I; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Baba SM; Immunology & Molecular Medicine, SKIMS, Srinagar, J&K, 190011, India., Koul A; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Zahoor W; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Afroze D; Department of Pathology, SKIMS, Srinagar, J&K, 190011, India., Lateef A; SRM University, Chennai, 603203, India., Manzoor U; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Bhat IA; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Sanadhya D; Department of Biochemistry, School of life Sciences, Jaipur National University, 302004, India., Bhat AR; Department of Neurosurgery, SKIMS, Srinagar, J&K, 190011, India., Ramzan AU; Department of Neurosurgery, SKIMS, Srinagar, J&K, 190011, India., Mohammad F; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India., Anwar I; Advanced Centre for Human Genetics, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, J&K, 190011, India.
Jazyk:	angličtina
Zdroj:	Future science OA [Future Sci OA] 2020 Dec 09; Vol. 7 (3), pp. FSO663. Date of Electronic Publication: 2020 Dec 09.
DOI:	10.2144/fsoa-2020-0057
Abstrakt:	Aim: The implications of molecular biomarkers IDH 1/2 mutations and MGMT gene promoter methylation were evaluated for prognostic outcome of glioma patients. Materials & Methods: Glioma cases were analyzed for IDH 1/2 mutations and MGMT promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Results: Mutations found in IDH 1/2 genes totaled 63.4% (N = 40) wherein IDH 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). IDH 1 mutants presented more, 60.5% in MGMT promoter-methylated cases (p = 0.03). IDH 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in MGMT methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p < 0.05). Conclusion: IDH 1/2 mutations proved independent prognostic factors in glioma and associated with MGMT methylation for better survival. Competing Interests: Financial & competing interests disclosure The current study was funded by Department of Science and technology, SERB Division, New Delhi (no. SB/SO/HS-036//2013). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. (© 2020 Arshad A. Pandith.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu